Navigation Links
Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
Date:7/9/2009

SHANGHAI, July 9 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd., (ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, today announces that it has expanded its integrated drug discovery research collaboration with Agios, the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of cancer metabolism. ChemPartner will provide integrated services in the areas of protein science, HTS, in vitro enzyme assay, cell biology, in vivo pharmacology, etc., for Agios' innovative R&D program to discover novel clinical candidates for oncology indications.

Michael Hui, founder and CEO of ChemPartner, said, "ChemPartner is pleased to build upon this existing collaboration and work closely with the experienced scientists at Agios to develop new clinical compounds for oncology indications. The partnership demonstrates the strength and breadth of our integrated drug discovery and development capabilities and this is a wonderful opportunity to share expertise and complement strengths."

"Due to the rapid success and progression of our pipeline and platform, Agios has experienced a need for significant resource assistance. ChemPartners has been able to help us address these needs quickly with high quality and quick responsiveness," said Michael Su, Vice President of Drug Discovery, Agios Pharmaceuticals. "ChemPartners' flexibility, scientific expertise, problem-solving skills as well as its comprehensive and integrated service platform have made them an invaluable partner in our continuing leadership strategy of the exciting, breakthrough field of cancer metabolism."

About Shanghai ChemPartner

Founded in 2003, Shanghai ChemPartner Company Ltd. (ChemPartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 80 pharmaceutical and biotech companies in the world. ChemPartner currently has a team of over 1,000 scientists including over 80 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies.

Further information is available at http://www.shangpharma.com .


'/>"/>
SOURCE Shanghai ChemPartner Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007
2. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
3. Cinpathogen Brings Together Over 40 Shanghai Area Hospitals at the First Annual Cinpathogen Hematology Conference
4. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
5. Shanghai CRO Service Alliance Adds Clinical Development Capabilities
6. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
7. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
8. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
9. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)...   Biostage, Inc. (Nasdaq: BSTG ... bioengineered organ implants to treat cancers and other life-threatening ... the closing on February 15, 2017 of its previously ... and warrants to purchase 20,000,000 shares of common stock, ... was priced at $0.40 per share of common stock, ...
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
(Date:2/16/2017)... LAFAYETTE, Indiana (PRWEB) , ... ... ... division of Albany Molecular Research Inc. has further extended its industry leading ... This service offers state-of-the-art cGMP techniques and methods for the ...
Breaking Biology Technology:
(Date:2/6/2017)... , Feb. 6, 2017 According ... security are driving border authorities to continue to ... reports there are 2143 Automated Border Control (ABC) ... currently deployed at more than 163 ports of ... 2013 to 2016 achieving a combined CAGR of ...
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
(Date:2/2/2017)... YORK , Feb. 2, 2017  EyeLock LLC, ... released a new white paper " What You Should ... The problem of ensuring user authenticity is a growing ... the authentication of users. However, traditional authentication schemes such ... Biometric authentication offers an elegant solution ...
Breaking Biology News(10 mins):